Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential

John Gatfield(Idorsia (Switzerland)), Oliver Nayler(Actelion (Switzerland))
Journal of Pharmacology and Experimental Therapeutics
May 6, 2017
Cited by 35


Related Papers